Q3 2023
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXRX | Sell | RECURSION PHARMACEUTICALS INcl a | $6,034,029 | -59.0% | 788,762 | -60.0% | 10.04% | -61.1% |
Q2 2023
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | ROVER GROUP INC | $42,415,099 | – | 8,638,513 | – | 74.22% | – | |
| RXRX | New | RECURSION PHARMACEUTICALS INcl a | $14,730,153 | – | 1,971,908 | – | 25.77% | – |
| ANGI | New | ANGI INC | $6,263 | – | 1,898 | – | 0.01% | – |
Q4 2022
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANGI | Exit | ANGI INC | $0 | – | -1,898 | – | -0.00% | – |
| RXRX | Exit | RECURSION PHARMACEUTICALS INcl a | $0 | – | -1,971,908 | – | -15.20% | – |
| Exit | ROVER GROUP INC | $0 | – | -11,518,019 | – | -27.88% | – | |
| POSH | Exit | POSHMARK INC | $0 | – | -5,012,539 | – | -56.92% | – |
Q2 2022
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| POSH | New | POSHMARK INC | $50,677,000 | – | 5,012,539 | – | 46.05% | – |
| New | ROVER GROUP INC | $43,308,000 | – | 11,518,019 | – | 39.36% | – | |
| RXRX | New | RECURSION PHARMACEUTICALS INcl a | $16,051,000 | – | 1,971,908 | – | 14.59% | – |
| ANGI | New | ANGI INC | $9,000 | – | 1,898 | – | 0.01% | – |